Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

@article{Rohde2008DeterminationOR,
  title={Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.},
  author={Gabriele Rohde},
  journal={Journal of chromatography. B, Analytical technologies in the biomedical and life sciences},
  year={2008},
  volume={872 1-2},
  pages={
          43-50
        }
}
A high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method allowing the sensitive and specific quantification of rivaroxaban (BAY 59-7939), a Factor Xa inhibitor in advanced development for the prevention and treatment of thromboembolic disorders, in human plasma is described. After precipitation of plasma proteins with methanol containing the internal standard followed by centrifugation, the plasma supernatant was injected directly onto the HPLC-MS/MS system… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 63 CITATIONS, ESTIMATED 38% COVERAGE

Diagnostic accuracy of thromboelastometry and its correlation with the HPLC-MS/MS quantification test

Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging

VIEW 2 EXCERPTS
CITES METHODS

FILTER CITATIONS BY YEAR

2011
2020

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019